Radiotherapy-drug Combinations in the Treatment of Glioblastoma: a Brief Review

Overview

Journal CNS Oncol

Specialty Oncology

Date 2022 May 23

PMID 35603818

Authors

Patrick G McAleavey

Gerard M Walls

Anthony J Chalmers

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) accounts for over 50% of gliomas and carries the worst prognosis of all solid tumors. Owing to the limited local control afforded by surgery alone, efficacious adjuvant treatments such as radiotherapy (RT) and chemotherapy are fundamental in achieving durable disease control. The best clinical outcomes are achieved with tri-modality treatment consisting of surgery, RT and systemic therapy. While RT-chemotherapy combination regimens are well established in oncology, this approach was largely unsuccessful in GBM until the introduction of temozolomide. The success of this combination has stimulated the search for other candidate drugs for concomitant use with RT in GBM. This review seeks to collate the current evidence for these agents and synthesize possible future directions for the field.

Citing Articles

Metformin and glioma: Targeting metabolic dysregulation for enhanced therapeutic outcomes.

Basheer H, Salman N, Abdullah R, Elsalem L, Afarinkia K Transl Oncol. 2025; 53:102323.

PMID: 39970627 PMC: 11876755. DOI: 10.1016/j.tranon.2025.102323.

Inhibition of CHI3L1 decreases N-cadherin and VCAM-1 levels in glioblastoma.

Rusak A, Gasior-Glogowska M, Sargenti A, Krzyzak E, Kotowski K, Mrozowska M Pharmacol Rep. 2024; 77(1):210-228.

PMID: 39607670 PMC: 11743419. DOI: 10.1007/s43440-024-00677-3.

Inhibition of CHI3L1 decreases N-cadherin and VCAM-1 levels in glioblastoma.

Rusak A, Gasior-Glogowska M, Sargenti A, Krzyzak E, Kotowski K, Mrozowska M Res Sq. 2024; .

PMID: 39399677 PMC: 11469515. DOI: 10.21203/rs.3.rs-4963939/v1.

Effect of Bee Venom on Glioblastoma Cancer: In Vitro and In Vivo Studies.

Chahla C, Rima M, Mouawad C, Roufayel R, Kovacic H, El Obeid D Molecules. 2024; 29(16).

PMID: 39203027 PMC: 11357583. DOI: 10.3390/molecules29163950.

A Whole-Transcriptomic Analysis of Canine Oral Melanoma: A Chance to Disclose the Radiotherapy Effect and Outcome-Associated Gene Signature.

Mucignat G, Montanucci L, Elgendy R, Giantin M, Laganga P, Pauletto M Genes (Basel). 2024; 15(8).

PMID: 39202425 PMC: 11353338. DOI: 10.3390/genes15081065.

References

Sim H, McDonald K, Lwin Z, Barnes E, Rosenthal M, Foote M . A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. Neuro Oncol. 2021; 23(10):1736-1749. PMC: 8485443. DOI: 10.1093/neuonc/noab111. View

Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T . Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2017; 20(5):674-686. PMC: 5892140. DOI: 10.1093/neuonc/nox208. View

Vecchio D, Daga A, Carra E, Marubbi D, Baio G, Neumaier C . Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019. Int J Cancer. 2014; 135(2):479-91. DOI: 10.1002/ijc.28680. View

McGranahan T, Therkelsen K, Ahmad S, Nagpal S . Current State of Immunotherapy for Treatment of Glioblastoma. Curr Treat Options Oncol. 2019; 20(3):24. PMC: 6394457. DOI: 10.1007/s11864-019-0619-4. View

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Penas-Prado M, Hess K, Fisch M, Lagrone L, Groves M, Levin V . Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 2014; 17(2):266-73. PMC: 4288521. DOI: 10.1093/neuonc/nou155. View

Fortin D, Morin P, Belzile F, Mathieu D, Pare F . Intra-arterial carboplatin as a salvage strategy in the treatment of recurrent glioblastoma multiforme. J Neurooncol. 2014; 119(2):397-403. DOI: 10.1007/s11060-014-1504-4. View

Gan H, Kaye A, Luwor R . The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 2009; 16(6):748-54. DOI: 10.1016/j.jocn.2008.12.005. View

Yver A . Osimertinib (AZD9291)-a science-driven, collaborative approach to rapid drug design and development. Ann Oncol. 2016; 27(6):1165-1170. DOI: 10.1093/annonc/mdw129. View

10.

Fulton B, Short S, James A, Nowicki S, McBain C, Jefferies S . PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clin Transl Radiat Oncol. 2018; 8:12-16. PMC: 5862667. DOI: 10.1016/j.ctro.2017.11.003. View

11.

Hu Z, Ott P, Wu C . Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2017; 18(3):168-182. PMC: 6508552. DOI: 10.1038/nri.2017.131. View

12.

Mann J, Ramakrishna R, Magge R, Wernicke A . Advances in Radiotherapy for Glioblastoma. Front Neurol. 2018; 8:748. PMC: 5775505. DOI: 10.3389/fneur.2017.00748. View

13.

Mangani D, Weller M, Roth P . The network of immunosuppressive pathways in glioblastoma. Biochem Pharmacol. 2016; 130:1-9. DOI: 10.1016/j.bcp.2016.12.011. View

14.

Wesolowski J, Rajdev P, Mukherji S . Temozolomide (Temodar). AJNR Am J Neuroradiol. 2010; 31(8):1383-4. PMC: 7966084. DOI: 10.3174/ajnr.A2170. View

15.

Fokas E, Prevo R, Pollard J, Reaper P, Charlton P, Cornelissen B . Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012; 3:e441. PMC: 3542617. DOI: 10.1038/cddis.2012.181. View

16.

Brown C, Alizadeh D, Starr R, Weng L, Wagner J, Naranjo A . Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016; 375(26):2561-9. PMC: 5390684. DOI: 10.1056/NEJMoa1610497. View

17.

Raso A, Vecchio D, Cappelli E, Ropolo M, Poggi A, Nozza P . Characterization of glioma stem cells through multiple stem cell markers and their specific sensitization to double-strand break-inducing agents by pharmacological inhibition of ataxia telangiectasia mutated protein. Brain Pathol. 2012; 22(5):677-88. PMC: 8057648. DOI: 10.1111/j.1750-3639.2012.00566.x. View

18.

Acharya M, Christie L, Hazel T, Johe K, Limoli C . Transplantation of human fetal-derived neural stem cells improves cognitive function following cranial irradiation. Cell Transplant. 2013; 23(10):1255-66. PMC: 3895108. DOI: 10.3727/096368913X670200. View

19.

Keskin D, Anandappa A, Sun J, Tirosh I, Mathewson N, Li S . Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2018; 565(7738):234-239. PMC: 6546179. DOI: 10.1038/s41586-018-0792-9. View

20.

Prados M, Chang S, Butowski N, DeBoer R, Parvataneni R, Carliner H . Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2008; 27(4):579-84. PMC: 2645859. DOI: 10.1200/JCO.2008.18.9639. View